Genesis plans to use the funding to help drugs discovered with artificial intelligence enter clinical trials. : This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit https://www.djreprints.com. https://www.wsj.com/articles/andreessen-co-leads-200-million-investment-in-biotech-startup-genesis-therapeutics-6c303ba8 Venture firm Andreessen Horowitz has co-led a $200 million investment in Genesis Therapeutics, a biotechnology startup that uses artificial intelligence to discover medicines against molecular targets that have thwarted drugmakers. Genesis is one of several companies applying AI in an effort to uncover novel medicines and make drug discovery more successful.